Wellgistics Health, Inc. Common Stock (WGRX)
Official sitePHARMACEUTICAL RETAILERS
Last updated: Jul 21, 2026 at 5:00 PM ET
Wellgistics Health, Inc. Common Stock (WGRX) Financials: Revenue, Profit and Cash Flow
Wellgistics Health, Inc. Common Stock reported revenue of $23.34M for the fiscal year ended Dec 31, 2025, up 28.7% from the year before. That year, net income was -$101.27M with a net margin of -433.9%, operating cash flow was -$10.86M and free cash flow was -$11.74M. The quarter ended Sep 30, 2026 had revenue of $2.67M and net income of $10.54M.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $23.34M | +28.7% | -27.5% | -401.7% | -433.9% |
| Dec 2024 | $18.13M | N/A | 9.7% | -33.9% | -37.8% |
| Dec 2023 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2022 | $32.78M | N/A | 17.5% | -10.4% | -8.4% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | $23.34M | $18.13M | $0 | $32.78M |
| Cost of revenue | $29.76M | $16.36M | $0 | $27.03M |
| Gross profit | -$6.43M | $1.77M | $0 | $5.75M |
| Research and development | $0 | $0 | $0 | $1.40K |
| Operating income | -$93.75M | -$6.15M | -$2.88M | -$3.42M |
| Net income | -$101.27M | -$6.86M | -$2.90M | -$2.74M |
| EBITDA | -$90.46M | -$4.91M | -$2.88M | -$369.03K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.67M | $1.78M | $1.56M | $1.67M | $3.01M | $7.79M | $10.86M | $12.41M | $5.67M | $44.54K | $0 | $34.37M |
| Gross profit | $431.88K | $182.20K | $170.22K | -$7.86M | $231.01K | $505.75K | $692.64K | $1.25M | $521.24K | -$2.61K | $0 | $2.77M |
| Operating income | -$3.37M | -$7.35M | -$6.02M | -$25.35M | -$31.55M | -$5.50M | -$31.35M | -$3.75M | -$1.74M | -$573.02K | -$79.76K | -$10.32M |
| Net income | $10.54M | -$18.36M | -$7.74M | -$27.85M | -$34.32M | -$6.67M | -$32.43M | -$4.33M | -$1.87M | -$574.33K | -$83.12K | -$11.80M |
Balance Sheet
As of Dec 2025, total debt of $23.49M exceeded cash and equivalents by $23.44M. Shareholder equity was negative, at -$12.45M, as total liabilities of $42.91M exceeded total assets of $30.46M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total assets | $30.46M | $57.33M | $338.36K | $0 |
| Current assets | $2.82M | $15.17M | $338.36K | $0 |
| Cash and equivalents | $42.57K | $1.03M | $1.36K | $0 |
| Total liabilities | $42.91M | $50.60M | $3.24M | $5.25K |
| Short-term debt | $10.89M | $11.93M | $0 | N/A |
| Long-term debt | $12.60M | $11.46M | $350.00K | N/A |
| Shareholder equity | -$12.45M | $6.73M | -$2.90M | -$5.25K |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $38.73M | $32.76M | $30.13M | $30.46M | $52.78M | $54.23M | $58.06M | $57.33M | $55.57M | $44.66M | $34.68M | $338.36K |
| Total liabilities | $38.56M | $52.26M | $45.19M | $42.91M | $46.00M | $53.32M | $53.58M | $50.60M | $45.59M | $45.62M | $34.68M | $3.24M |
| Cash and equivalents | $476.60K | $2.46M | $51.73K | $42.57K | $4.23M | $419.94K | $2.52M | $1.03M | $793.15K | $2.07M | $917.14K | $1.36K |
| Shareholder equity | -$1.70M | -$19.50M | -$15.06M | -$12.45M | $6.78M | $905.25K | $4.48M | $6.73M | $9.99M | -$967.13K | -$93 | -$2.90M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating cash flow | -$10.86M | -$1.22M | -$349.14K | $0 |
| Capital expenditures | $881.53K | $377.29K | $0 | $0 |
| Free cash flow | -$11.74M | -$1.60M | -$349.14K | $0 |
| Investing cash flow | -$881.53K | $469.07K | $0 | N/A |
| Financing cash flow | $10.75M | $1.78M | $350.50K | $0 |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.90M | -$2.89M | -$3.41M | -$6.29M | -$1.14M | -$2.08M | -$1.35M | -$2.62M | $1.04M | $329.96K | $31.24K | -$462.06K |
| Capital expenditures | N/A | N/A | $205.10K | $255.38K | $405.06K | $131.93K | $273.13K | $112.44K | $217.05K | $4 | $3 | $0 |
| Free cash flow | N/A | N/A | -$3.62M | -$6.55M | -$1.54M | -$2.21M | -$1.62M | -$2.74M | $820.54K | $329.95K | $31.23K | -$462.06K |
Frequently Asked Questions About WGRX
What is Wellgistics Health, Inc. Common Stock's annual revenue?
Wellgistics Health, Inc. Common Stock reported revenue of $23.34M for the fiscal year ended Dec 31, 2025.
How fast is Wellgistics Health, Inc. Common Stock's revenue growing?
Revenue was up 28.7% for the fiscal year ended Dec 31, 2025 compared with the year before.
Is Wellgistics Health, Inc. Common Stock profitable?
No. Wellgistics Health, Inc. Common Stock reported net income of -$101.27M for the fiscal year ended Dec 31, 2025, with a net margin of -433.9%.
How much free cash flow does WGRX generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$10.86M minus capital expenditures of $881.53K produced free cash flow of -$11.74M.
How much debt does Wellgistics Health, Inc. Common Stock have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $12.60M, short-term debt of $10.89M and cash and equivalents of $42.57K.
WGRX pages: Overview, Financials